NCT02740985: A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies

NCT02740985
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: History of seizures, central nervous system tumors or CNS metastasis
https://ClinicalTrials.gov/show/NCT02740985

Comments are closed.

Up ↑